Vericel Corporation
Vericel Corporation (VCEL) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
vcel · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Vericel Corporation (VCEL) measures how much investors pay for each dollar of the company's trailing earnings. VCEL's current PE ratio of 84.62x is calculated by dividing its stock price of $35.77 by its TTM earnings per share of $0.42. −70.4% discount vs 5Y avg 285.6x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 3 fiscal years · Front-end computedMinQ1 · 25%258.9x
MedianQ3 · 75%487.6x
Max
At 84.62x, VCEL's current P/E is lower than in 0% of its annual fiscal year readings over the past 3 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Vericel CorporationYou VCEL | $1.8B | 84.62x | -19.8% | $0.42 |
 Aurinia Pharmaceuticals Inc. AUPH | $2.0B | 7.46x | -92.9% | $2.14 |
 Edgewise Therapeutics, Inc. EWTX | $3.7B | N/A | — | -$1.63 |
 Structure Therapeutics Inc. GPCR | $2.2B | N/A | — | -$2.39 |
 Harmony Biosciences Holdings, Inc. HRMY | $1.9B | 13.56x | -87.2% | $2.76 |
 Mesoblast Limited MESO | $1.8B | N/A | — | -$0.85 |
 MannKind Corporation MNKD | $1.0B | 295.58x | +180.1% | $0.02 |
Industry Average 3 peers with valid PE | — | 105.53x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 110.29x | $0.33 | -57.4% | |
2024-12-31 FY2024 | 258.85x | $0.21 | — | |
2023-12-31 FY2023 | — | $-0.07 | — | |
2022-12-31 FY2022 | — | $-0.35 | — | |
2021-12-31 FY2021 | — | $-0.16 | — | |
2020-12-31 FY2020 | 487.58x | $0.06 | — | |
2019-12-31 FY2019 | — | $-0.22 | — | |
2018-12-31 FY2018 | — | $-0.20 | — | |
2017-12-31 FY2017 | — | $-0.52 | — | |
2016-12-31 FY2016 | — | $-0.85 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Vericel Corporation (VCEL) measures how much investors pay for each dollar of the company's trailing earnings. VCEL's current PE ratio of 84.62x is calculated by dividing its stock price of $35.77 by its TTM earnings per share of $0.42.
Frequently asked questions
VCEL pe ratio · 6 questionsVCEL's current PE ratio is 84.62x as of 2026-06-09, based on a stock price of $35.77 and TTM EPS of $0.42. Data sourced from Financial Modeling Prep via VCEL's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Vericel Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09